Cargando…
RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS‐mutated lung adenocarcinoma
OBJECTIVE: Advanced lung cancers carrying Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation remain a group that lacks effective treatments. Receptor activator of nuclear factorκB ligand (RANKL) has been demonstrated to drive malignant phenotypes in lung cancer; however, its role in KRAS‐mut...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212663/ https://www.ncbi.nlm.nih.gov/pubmed/37021520 http://dx.doi.org/10.1111/1759-7714.14882 |